| pubmed-article:1505853 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1505853 | lifeskim:mentions | umls-concept:C0032659 | lld:lifeskim |
| pubmed-article:1505853 | lifeskim:mentions | umls-concept:C0162867 | lld:lifeskim |
| pubmed-article:1505853 | lifeskim:mentions | umls-concept:C0242184 | lld:lifeskim |
| pubmed-article:1505853 | lifeskim:mentions | umls-concept:C0017725 | lld:lifeskim |
| pubmed-article:1505853 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1505853 | lifeskim:mentions | umls-concept:C0205251 | lld:lifeskim |
| pubmed-article:1505853 | lifeskim:mentions | umls-concept:C0069772 | lld:lifeskim |
| pubmed-article:1505853 | lifeskim:mentions | umls-concept:C0547047 | lld:lifeskim |
| pubmed-article:1505853 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:1505853 | pubmed:dateCreated | 1992-9-21 | lld:pubmed |
| pubmed-article:1505853 | pubmed:abstractText | Evoked potentials were recorded in rat cerebral cortical slices. The amplitude of the evoked potential was reduced by perfusion with hypoxic (0-25%) or low glucose (0-5 mM) media in a concentration-dependent manner, and the evoked potentials disappeared under severe conditions (below 15% O2, below 3 mM glucose). We investigated the protective effects of oxiracetam on the decrease in evoked potentials under hypoxic (15% O2) and low glucose (3 mM glucose) conditions. Drugs were perfused from 45 min before hypoxic or low glucose perfusion to the end of the experiment. Oxiracetam (10(-6)-10(-5) M) dose-dependently minimized the amplitude reduction of evoked potentials and prolonged their disappearance time. At a concentration of 10(-5) M, oxiracetam protected against the disappearance of evoked potential in 5 of the 6 samples under hypoxic conditions and in all 6 samples under low glucose conditions. Indeloxazine (5 x 10(-6)-10(-5) M) and bifemelane (5 x 10(-6)-10(-5) M) prevented the reduction of the amplitude of evoked potentials under low glucose conditions. However, these drugs had no effect at a concentration of 10(-6) M. These data indicate that oxiracetam has a protective effect against neuronal dysfunction and that this effect develops at a lower concentration than those of indeloxazine and bifemelane. | lld:pubmed |
| pubmed-article:1505853 | pubmed:language | jpn | lld:pubmed |
| pubmed-article:1505853 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1505853 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1505853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1505853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1505853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1505853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1505853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1505853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1505853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1505853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1505853 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1505853 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:1505853 | pubmed:issn | 0015-5691 | lld:pubmed |
| pubmed-article:1505853 | pubmed:author | pubmed-author:ShinodaYY | lld:pubmed |
| pubmed-article:1505853 | pubmed:author | pubmed-author:HoriNN | lld:pubmed |
| pubmed-article:1505853 | pubmed:author | pubmed-author:HokonoharaTT | lld:pubmed |
| pubmed-article:1505853 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1505853 | pubmed:volume | 99 | lld:pubmed |
| pubmed-article:1505853 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1505853 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1505853 | pubmed:pagination | 123-33 | lld:pubmed |
| pubmed-article:1505853 | pubmed:dateRevised | 2011-7-27 | lld:pubmed |
| pubmed-article:1505853 | pubmed:meshHeading | pubmed-meshheading:1505853-... | lld:pubmed |
| pubmed-article:1505853 | pubmed:meshHeading | pubmed-meshheading:1505853-... | lld:pubmed |
| pubmed-article:1505853 | pubmed:meshHeading | pubmed-meshheading:1505853-... | lld:pubmed |
| pubmed-article:1505853 | pubmed:meshHeading | pubmed-meshheading:1505853-... | lld:pubmed |
| pubmed-article:1505853 | pubmed:meshHeading | pubmed-meshheading:1505853-... | lld:pubmed |
| pubmed-article:1505853 | pubmed:meshHeading | pubmed-meshheading:1505853-... | lld:pubmed |
| pubmed-article:1505853 | pubmed:meshHeading | pubmed-meshheading:1505853-... | lld:pubmed |
| pubmed-article:1505853 | pubmed:meshHeading | pubmed-meshheading:1505853-... | lld:pubmed |
| pubmed-article:1505853 | pubmed:meshHeading | pubmed-meshheading:1505853-... | lld:pubmed |
| pubmed-article:1505853 | pubmed:meshHeading | pubmed-meshheading:1505853-... | lld:pubmed |
| pubmed-article:1505853 | pubmed:meshHeading | pubmed-meshheading:1505853-... | lld:pubmed |
| pubmed-article:1505853 | pubmed:meshHeading | pubmed-meshheading:1505853-... | lld:pubmed |
| pubmed-article:1505853 | pubmed:meshHeading | pubmed-meshheading:1505853-... | lld:pubmed |
| pubmed-article:1505853 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1505853 | pubmed:articleTitle | [Effects of oxiracetam on the decrease in population spikes in hypoxic and low glucose media]. | lld:pubmed |
| pubmed-article:1505853 | pubmed:affiliation | Research Laboratories TOYO JOZO Co., Ltd., Shizuoka, Japan. | lld:pubmed |
| pubmed-article:1505853 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1505853 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:1505853 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:1505853 | pubmed:publicationType | English Abstract | lld:pubmed |
